Galectin 3 Protein (LGALS3) (AA 2-250)

Catalog No. ABIN2667416

Product Details

Target: Galectin 3 (LGALS3)

Protein Type: Recombinant

Biological Activity: Active

Protein Characteristics: AA 2-250

Origin: Human

Source: Escherichia coli (E. coli)

Application: ELISA, Flow Cytometry (FACS)

Purity: >95 % , as determined by Coomassie stained SDS-PAGE.

Sterility: 0.22 μm filtered

Endotoxin Level:

Less than 0.1 EU per μg of protein as determine by the LAL method.

Application Details

Application Notes: Optimal working dilution should be determined by the investigator.

Comment:

Biological activity: Recombinant human galectin-3 is able to agglutinate human red blood cells with an ED50 of 1.0 - 4.0 μg/ml, corresponding to a specific activity of 2.5 - 10.0 x 105 units/mg.

Restrictions: For Research Use only

Handling

Format: Liquid

Reconstitution: For maximum results, quick spin vial prior to opening. Stock solutions should be prepared at no less than 10 μg/mL in sterile buffer (PBS, HPBS, DPBS, and EBSS) containing carrier protein such as 1 % BSA or HSA. After dilution, the cytokine can be stored between 2 °C and 8 °C for one month or from -20 °C to -70 °C for up to 3 months.

Concentration: 200 μg/mL

Buffer: 0.22 μm filtered protein solution is in 10 mM NaH2PO4, 0.3 M NaCl, 2 mM DTT, pH 7.2.

Preservative: Dithiothreitol (DTT)

Precaution of Use: This product contains Dithiothreitol (DTT): a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Handling Advice: Avoid repeated freeze/thaw cycles.

Storage: -20 °C

Storage Comment: Unopened vial can be stored between 2°C and 8°C for three months, at -20°C for six months, or at -70°C for one year.

Target Details

Target: Galectin 3 (LGALS3)

Alternative Name: Galectin-3 (LGALS3 Products)

Synonyms: CBP 35 Protein, Gal-3 Protein, Galectin-3 Protein, leg3 Protein, galactoside-binding Protein, galectin-3 Protein, lectin Protein, soluble Protein, CBP35 Protein, GAL3 Protein, GALBP Protein, GALIG Protein, L31 Protein, LGALS2 Protein, MAC2 Protein, MGC52947 Protein, MGC75803 Protein, LGALS3 Protein, gal-3 Protein, GBP Protein, L-34 Protein, Mac-2 Protein, gal3 Protein, galectin 3 Protein, Galectin-3 Protein, avian beta-defensin 3 Protein, lectin, galactoside-binding, soluble, 3 L homeolog Protein, lectin, galactoside-binding, soluble, 3 Protein, galectin 2 Protein, lectin, galactose binding, soluble 3 Protein, LGALS3 Protein, leg3 Protein, AvBD3 Protein, lgals3.L Protein, lgals3 Protein, LGALS2 Protein, Lgals3 Protein

Target Type: Chemical

Background: Galectin-3 is a member of the lectin family, which includes 15 mammalian lectin members. Like all galectins, galectin-3 contains a carbohydrate recognition binding domain of about 130 amino acids that enables the specific binding of β-galactosides. This protein has been shown to be involved in cell adhesion, cell activation, chemoattraction, cell growth and differentiation, cell cycle, and apoptosis. Galectin-3 induces pro-inflammatory cytokines and inhibits Th2 type cytokine production. It chemoattracts monocytes and macrophages, and activates and degranulates basophils and mast cells. It was reported that galectin-3 knock-out mice demonstrated reduced phagocytic properties in macrophages and Kupffer cells, indicating that this protein is involved in macrophage phagocytosis. Galectin-3 has been shown to be involved in cancer, inflammation, fibrosis, heart disease, and stroke. It has also been shown that the expression of galectin-3 is implicated in a variety of processes associated with heart failure, including myofibroblast proliferation, tissue repair, inflammation, fibrogenesis, and ventricular remodeling. In addition, galectin-3 was found to contribute to tumor cell evasion of the immune system. Galectin-3 is increasingly being used as a diagnostic marker for different cancers. It can be screened for and used as a prognostic factor to predict the progression of the cancer. Overexpression of galectin-3 is associated with neoplastic transformation, enhancement of tumor cell adhesion to the extracellular matirx, and the subsequent metastatic spreading of cancer cells.

Molecular Weight: The 270 amino acid recombinant protein has a predicted molecular mass of approximately 28.3 kDa. The protein migrates above 40 kDa by SDS-PAGE in DTT-reducing and non-reducing conditions. The predicted N-terminal amino acid is His.

Pathways: RTK Signaling